CytRx Corporation Reports First Quarter 2019 Financial Results

Author's Avatar
May 15, 2019
Article's Main Image

Out-licensed Assets Aldoxorubicin and Arimoclomol Rapidly Advancing into Multiple Indications of High Unmet Need

CytRx Stands to Receive Significant Future Milestone Payments and Royalties from Licensing Agreements

PR Newswire